Preliminary results of a phase I, first-in-human, dose escalation study of IMM2902 in patients with HER2-expressing advanced solid tumors

• Published in: Journal of clinical oncology Vol. 41; no. 16_suppl; p. e15185
• Main Authors: Zhang, Jian, Zhao, Chuanhua, Cheng, Ying, Zhu, Liming, Song, Zhengbo, Xu, Nong, Wang, Zhen, Wang, Yanping, Du, Yiqun, Jing, Deqiang, Chen, Dinglu, Qu, Qiaofeng, Zhao, Xiwen, Li, Wei, Lu, Qiying, Tian, Wenzhi, Xu, Jianming
• Format: Journal Article
• Language: English
• Published: American Society of Clinical Oncology 01.06.2023

e15185Background: IMM2902 is a novel recombinant bispecific fusion protein containing SIRPα binding domain trapped to the light chain of a humanized anti-HER2 antibody. With its high affinity to HER2 and CD47 on tumor cell membrane, IMM2902 can drive several anti-tumoral killing mechanisms such as d...